Page 2,078«..1020..2,0772,0782,0792,080..2,0902,100..»

Woman grows a nose on her spine after experimental stem cell treatment goes awry

Posted: July 9, 2014 at 3:52 am

A female patient in the US has grown a nose on her back following a failed experimental stem cell treatment that was intended to cure her paralysis. The nose-like growth, which was producing a thick mucus-like material, has recently been removed as it was pressing painfully on herspine. If you ever needed an example of the potential perils of stem cell therapy, and just how little we actually know about the function of stem cells, this is it. Its also notable that this stem cell therapy was carried out in a developed country, as part of an approved trial (apparently unwanted growths are more common in developing nations with less stringent medical safeguards).

Eight years ago, olfactory stem cells were taken from the patients nose and implanted in her spine. The stem cells were meant to turn into nerve cells that would help repair the womans spine, curing her of paralysis. Instead, it seems they decided to do what they were originally meant to do and attempt to build a nose. Over a number of years, the nose-like growth eventually became big enough and nosy enough to cause pain and discomfort to the patient. As reported by New Scientist, surgeons removed a 3-centimetre-long growth, which was found to be mainly nasal tissue, as well as bits of bone and tiny nerve branches that had not connected with the spinal nerves. [DOI: 10.3171/2014.5.SPINE13992 - "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient"]

Your olfactory system. 1 is the olfactory bulb (the bit of your brain that processes smells); 6 is the olfactory receptors that bind to specific chemicals (odors). [Image credit: Wikipedia]

What went wrong, then? Basically, at the top of your nasal passages there is the olfactory mucosa. This region contains all of the machinery for picking up odors, and the neurons for sending all of that data off to your brains olfactory bulb for processing. Cells from this region can be easily and safely harvested, and with the correct processing they behave just like pluripotent embryonic stem cells that can develop into many other cell types. These olfactory stem cells could develop into cartilage, or mucus glands, or neurons. The researchers obviously wanted the latter, to cure the patients spinal nerve damage but seemingly they got it wrong, and thus she sprouted a second nose. Moving forward, newer olfactory stem cell treatments have an isolation stage to prevent this kind of thing from happening. [Read:The first 3D-printed human stem cells.]

Its important to note that medicine, despite being carried out primarily on humans, is still ultimately a scientific endeavor that requires a large amount of trial and error. In the western world, its very, very hard to get a stem cell therapy approved for human trials without lots of animal testing. Even then, the therapies are often only used on people who have nothing to lose. Obviously its hard to stomach news like this, and Im sure that stem cell critics will be quick to decry the Frankensteinian abomination created by these scientists. But when you think about the alternative no advanced medicine and significantly reduced lifespans for billions of people then really, such experimental treatments are nothing to sneeze at.

More:
Woman grows a nose on her spine after experimental stem cell treatment goes awry

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Woman grows a nose on her spine after experimental stem cell treatment goes awry

Research in sphere of stem cells – Video

Posted: July 8, 2014 at 11:45 am


Research in sphere of stem cells
Research in the field of stem cells in Kazakhstan is a relatively a new science. However, experiments of National Research Medical Center allowed improving t...

By: Kazakh TV

Link:
Research in sphere of stem cells - Video

Posted in Stem Cell Videos | Comments Off on Research in sphere of stem cells – Video

Dental pulp stem cells promote the survival and regeneration of retinal cells after injury

Posted: July 8, 2014 at 7:47 am

PUBLIC RELEASE DATE:

7-Jul-2014

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research

Researchers at the University of Birmingham, UK, led by Dr. Ben Scheven, Dr. Wendy Leadbeater and Ben Mead have discovered that stem cells isolated from the teeth, termed dental pulp stem cells (DPSC), can protect retinal ganglion cells (RGCs) from death following injury and promote regeneration of their axons along the optic nerve.

RGC loss is the leading cause of blindness and can arise through traumatic injury or degenerative diseases such as glaucoma. Neurotrophic factors (NTFs), which travel along the axon of a neuron to a cell body act as survival signals however, following injury or disease, this supply is lost and RGCs die. Supplementation of injured RGC with an alternative source of NTFs is paramount to protecting them from death.

The study, reported on Neural Regeneration Research (Vol. 9, No. 6, 2014), confirmed that DPSCs naturally express multiple NTFs which can supplement the lost supply of NTF and protect RGCs from death as well as promote regeneration of their axons. "Cell therapy is a promising treatment option as it provides a potentially limitless source of multiple growth factors for injured neurons", stressed first author Ben Mead. He also said "For clinical application, comparisons with other stem cells as well as development of safe delivery mechanisms are to be investigated in the future".

###

Article: "Dental pulp stem cells, a paracrine-mediated therapy for the retina" by Ben Mead1, 2, Ann Logan1, Martin Berry1, Wendy Leadbeater1, Ben A. Scheven2

(1 Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United Kingdom; 2 School of Dentistry, University of Birmingham, Birmingham B4 6NN, United Kingdom)

Mead B, Logan A, Berry M, Leadbeater W, Scheven BA. Dental pulp stem cells, a paracrine-mediated therapy for the retina. Neural Regen Res. 2014;9(6):577-578.

Link:
Dental pulp stem cells promote the survival and regeneration of retinal cells after injury

Posted in Stem Cells | Comments Off on Dental pulp stem cells promote the survival and regeneration of retinal cells after injury

Top Gilbert Pain Management Center, Arizona Pain Specialists, Now Offering Over 25 Nonoperative Back Pain Treatments

Posted: July 8, 2014 at 7:46 am

Gilbert, Arizona (PRWEB) July 08, 2014

The top Gilbert pain management clinic, Arizona Pain Specialists, is now offering over 25 effective back pain treatment options. The Arizona pain management center has now added regenerative medicine options along with cutting edge back pain treatments, which often provide over a year of pain relief. Call (480) 535-6722 to take advantage of the options.

Back pain affects 90% of individuals at some point. It may be disabling and prevent those affected from working, playing with one's kids or enjoying life. Arizona Pain continues to add back pain treatment options at its Gilbert location, combining both traditional and alternative therapies for optimal relief.

Board Certified pain management doctors work closely with chiropractors, acupuncturists and physical rehabilitation providers to customize treatment regimens for patients. New additions to the options include regenerative medicine treatments with stem cell procedures. These include both amniotic and bone marrow derived procedures.

Cutting edge additions to the interventional procedures include spinal cord stimulator implants and radiofrequency ablation procedures. These are excellent options for those suffering from chronic low back pain to provide much needed relief.

The Gilbert chiropractors at Arizona Pain offer revolutionary spinal decompression therapy, which is FDA cleared and effective in over 85% of patients. With all of the options available now with pain management Gilbert AZ trusts, Arizona Pain achieves over 95% success rates.

Over 50 insurance plans are accepted at the Center including PPO's, some HMO's, Medicare, Medicaid, personal injury liens, workers compensation and self pay as well. Call (480) 535-6722 for more information and scheduling.

Here is the original post:
Top Gilbert Pain Management Center, Arizona Pain Specialists, Now Offering Over 25 Nonoperative Back Pain Treatments

Posted in Regenerative Medicine | Comments Off on Top Gilbert Pain Management Center, Arizona Pain Specialists, Now Offering Over 25 Nonoperative Back Pain Treatments

Why stem cell therapy is not available in Europe or United States of America – Video

Posted: July 8, 2014 at 7:41 am


Why stem cell therapy is not available in Europe or United States of America
In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Explains, Why stem cell therapy is not available...

By: Neurogen Brain and Spine Institute

Read the original:
Why stem cell therapy is not available in Europe or United States of America - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Why stem cell therapy is not available in Europe or United States of America – Video

What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ? – Video

Posted: July 8, 2014 at 7:41 am


What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ?
Dr. Nandini Gokulchandran from Neurogen Brain and Spine Institute explains what goes wrong in the brain of a child with Autism Spectrum Disorder? Stem Cell Therapy done at Dr Alok Sharma...

By: Neurogen Brain and Spine Institute

Read the original here:
What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ? - Video

Posted in Cell Therapy | Comments Off on What Goes Wrong in the Brain of a Child with Autism Spectrum Disorder ? – Video

Spinal cord mass arising from neural stem cell therapy

Posted: July 8, 2014 at 7:41 am

PUBLIC RELEASE DATE:

8-Jul-2014

Contact: Jo Ann Eliason jaeliason@thejns.org 434-982-1209 Journal of Neurosurgery Publishing Group

Charlottesville, VA (July 8, 2014). A spinal mass was identified in a young woman with complete spinal cord injury 8 years after she had undergone implantation of olfactory mucosal cells in the hopes of regaining sensory and motor function. The case is reported and discussed in "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient. Case report," by Brian J. Dlouhy, MD, Olatilewa Awe, MD, Rajesh C. Rao, MD, Patricia A. Kirby, MD, and Patrick W. Hitchon, MD, published today online, ahead of print, in the Journal of Neurosurgery: Spine. The authors state that this is the first report of a spinal cord mass arising from spinal cord cell transplantation and neural stem cell therapy, and they caution that physicians should be vigilant in their follow-up of patients who undergo stem cell interventions.

In its natural state, the olfactory mucosa lines the roof of the nasal cavity, adjacent to the respiratory mucosa that lines the lower nasal cavity. In addition to smell receptor neurons, the olfactory mucosa contains progenitor cells (also known as adult stem cells) and olfactory ensheathing cellsboth of which have been shown to aid in the repair of the injured spinal cord in laboratory studies and in humans. The respiratory mucosa, on the other hand contains mucus-secreting goblet cells and mucus and serous fluidproducing cells.

The patient was 18 years old when she sustained a fracture dislocation at the 10th and 11th thoracic vertebral level in a motor vehicle accident. Despite surgery to stabilize the spine, the injury rendered the patient paraplegic. Three years later, in the hopes of regaining sensory and motor function in her lower limbs, the young woman underwent additional surgery at an institution outside the United States, during which an autograft of olfactory mucosa was placed in her spinal canal at the site of injury. Eight years after the experimental therapy, the woman sought medical care for mid- to lower-back pain at the University of Iowa Hospitals and Clinics. On neurological examination, she showed no sign of clinical improvement from the olfactory mucosal cell implantation, and imaging studies revealed a mass in her spinal canal pressing against the spinal cord. This mass was the source of the patient's pain.

Following surgery to remove the symptom-producing mass at the University of Iowa, a tissue analysis showed that the mass contained a small proportion of nonfunctional tiny nerve branches, whose appearance led the authors to suspect the nerve branches developed from transplanted neural stem-like cells. The tissue analysis also demonstrated that most of the mass consisted of multiple cysts lined with respiratory mucosa and underlying submucosal glands and goblet cells. Abundant mucus-like material was also found in the mass. Accumulation of this material over time produced the patient's symptoms.

The authors describe various ways of extracting olfactory mucosa cells for implantation. In this particular case, a portion of olfactory mucosa was transplanted; in other trials, olfactory ensheathing cells have been extracted from olfactory mucosa and purified prior to implantation. The authors suggest that the choice of bulk olfactory mucosa rather than purified olfactory ensheathing cells or stem cells as an autograft may lead to the development of a mass containing functional respiratory mucosal cells.

The authors point out that a rare case of spinal cord complication such as this should not discourage stem cell research and/or the transition of promising research to the clinical setting. However, the authors indicate the need for a better understanding of what can occur and urge clinicians to extend the monitoring period in patients treated with neural stem cell therapy for many years in case an adverse event such as this should arise. In summarizing the take-away message of the paper, Dr. Brian Dlouhy stated: "Exhaustive research on how transplanted cells divide, differentiate, and organize in animal models of disease, especially spinal cord injury, is critical to providing safe and effective treatments in humans."

###

Read the original post:
Spinal cord mass arising from neural stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Spinal cord mass arising from neural stem cell therapy

Hue Hospital Succeeds in Treating Cancer with Stem Cell

Posted: July 8, 2014 at 7:40 am

Doctors of Hue Central Hospital have used stem cell transplantation to successfully treat a cancer patient of the last stage. The Hue Central Hospital announced on June 26 that its doctors have cured Le Thi Sau, 52, who was suffering ovarian cancer in the last stage, with stem cell transplant. The operation is the success of the scientific project Using stem cell in breast cancer and cervical cancer managed by Professor Nguyen Duy Thang, deputy head of the hospital. Adult stem cells have been used to treat certain cancers through bone marrow transplants. In this therapy, the stem cells that give rise to the different blood cells in the body are transplanted into the bone marrow of the patient, where they regenerate the blood. The project was given green light to carry out in the Hue Central Hospital by the Ministry of Science and Technology. Professor Nguyen Duy Thang said the success of this method will pave the way for next operations on breast and ovarian cancer patients. In the time ahead, the hospital continues to treat two other cancer female patients with the stem cell treatment. It is hoped that the treatment will save many cancer patients. (www.saigon-gpdaily.com.vn June 27)

Follow this link:
Hue Hospital Succeeds in Treating Cancer with Stem Cell

Posted in Cell Therapy | Comments Off on Hue Hospital Succeeds in Treating Cancer with Stem Cell

Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by …

Posted: July 7, 2014 at 10:48 pm

NEW YORK, July 7, 2014 /PRNewswire/ --Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company focused on developing and commercializing human pluripotent stem cell technology in the field of regenerative medicine. The company is currently conducting clinical trials for treating dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD), as well as several clinical and preclinical programs for other ocular therapies. Outside of ophthalmology, ACTC also has a preclinical development pipeline focused on autoimmune diseases, inflammatory diseases and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and other cell therapy research programs.

As the worldwide population has continued to age, so too has the need for regenerative medicine. In fact, by 2050, the number of people in the world over the age of 65 is expected to rise to 1.5 billion nearly triple the amount today. Unsurprisingly, as this demographic shift occurs over the next 35 years, health care expenditures are projected to increase rapidly as well. For example, in the US, the share of GDP devoted to healthcare is estimated to reach 34% by 2040 from about 18% just a few years ago. Considering the majority of treatments for chronic and/or life-threatening diseases that are available today only treat symptoms rather than offer a cure for the underlying cause, regenerative medicine such as the stem cell therapies being developed by ACTC are aimed at addressing this unmet and growing need.

Macular degeneration (i.e. age-related macular degeneration, or AMD) is a medical condition that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. This indication is the leading cause of blindness and visual impairment in adults over fifty years of age. Currently, it is estimated that there are approximately 30 million people worldwide who suffer from AMD ranging from early-stage to late-stage (i.e. legal blindness), with an estimated market size of around $30 billion. Further, in an article in the journal, Lancet projected that the number of people globally with AMD will be 196 million in 2020, growing to 288 million by 2040.

A full in-depth analyst report on ACTC that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-ACTC-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

Read the original:
Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by ...

Posted in Stem Cell Therapy | Comments Off on Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by …

Scientists use stem cells to regenerate human corneas

Posted: July 6, 2014 at 8:55 pm

Scientists have developed a new technique to regrow human corneas.

Using key tracer molecules, researchers have been able to hunt down elusive cells in the eye capable of regeneration and repair.

They transplanted these regenerative stem cells into mice creating fully functioning corneas.

Writing in the journal Nature, they say this method may one day help restore the sight of victims of burns and chemical injuries.

Limbal stem cells are crucial for healthy eyesight these cells work to maintain, repair and completely renew our corneas every few weeks.

Without them the cornea the transparent outermost layer of the eye would become cloudy and our vision disrupted.

A deficiency of these cells due to disease or damage through injury to the eye is among the commonest reasons behind blindness worldwide.

But the cells have so far been extremely difficult to identify, buried in a matrix of other structures in the limbal part of the eye the junction between the cornea and the white of the eye (the sclera).

Now scientists from the Massachusetts Eye and Ear Infirmary, Boston Childrens Hospital, Brigham and Womens Hospital and the VA Boston Healthcare System have identified a key tracer molecule known as ABCB5 naturally present on the surface of limbal stem cells.

Though ABCB5 has been known about for some time in other parts of the body, this is the first time it has been spotted on LSCs, helping to single out these elusive cells.

View post:
Scientists use stem cells to regenerate human corneas

Posted in Stem Cells | Comments Off on Scientists use stem cells to regenerate human corneas

Page 2,078«..1020..2,0772,0782,0792,080..2,0902,100..»